Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates

A protein conjugate, immunogenic technology, which can be used in multivalent vaccines, active ingredients of heterocyclic compounds, and medical preparations of non-active ingredients, etc., and can solve problems such as the increase in the prevalence of pneumococcus

Pending Publication Date: 2020-05-01
MERCK SHARP & DOHME BV
View PDF60 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the prevalence of pneumococci expressing serotypes not present in the vaccine is increasing

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
  • Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
  • Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0158] Embodiment 1: Preparation of Streptococcus pneumoniae capsular polysaccharide

[0159] Methods of culturing pneumococci are well known in the art. See, eg, Chase, 1967, Methods of Immunology and Immunochemistry 1:52. Methods of preparing pneumococcal capsular polysaccharides are also well known in the art. See eg European Patent No. EP 0 497 524 B1. The method described below generally follows that described in European Patent No. EP 0497 524 B1 and is generally applicable to all pneumococcal serotypes unless specifically modified.

[0160] Isolates of pneumococcal subtype 24F were obtained from the Merck Culture Collection. Subtypes can be differentiated based on the Quelling reaction using specific antisera if desired. See, eg, US Patent No. 5,847,112. The isolates obtained from the clonal isolation were further clonally isolated by sequential plating in two stages on agar plates consisting of an animal component-free medium containing soy peptone, yeast extract ...

Embodiment 2

[0167] Embodiment 2: NMR structure analysis of polysaccharide

[0168] The strategy for determining the structure of polysaccharides involves a multi-step process performed essentially as described by Abeygunawardana et al., Determination of the Chemical Structure of Complex Polysaccharides by Heteronuclear NMR Spectroscopy in Advances in Biophysical Chemistry 1993, Vol 3, pages 199-249, JAI Press Inc. The purified polysaccharides were examined using standard 1D and 2D NMR techniques. Finally, use 31 P NMR detects the presence of phosphate esters in polysaccharides.

[0169] Monosaccharide residue assignment (assignment) by 1 H- 1 H COZY, double quantum filtering homonuclear COZY and total correlation spectroscopy (TOCSY) were performed. Determined by the combination of heteronuclear single quantum coherence spectroscopy (HSQC) and HSQC-TOCSY 13 C chemical shift. Multiple edited HSQC was used to distinguish methylene from methine. Inter-residue linkage was determined by...

Embodiment 3

[0183] Example 3: Conjugation of S. pneumoniae serotype 24F polysaccharide to CRM197 using reductive amination in dimethylsulfoxide

[0184] Polysaccharides are dissolved, sized to target molecular weight, chemically activated and buffer exchanged by ultrafiltration. The activated polysaccharide and purified CRM197 were separately lyophilized and then redissolved in dimethyl sulfoxide (DMSO). The redissolved polysaccharide and CRM197 solutions were then combined and conjugated as described below. The resulting conjugate was purified by ultrafiltration before a final 0.2 micron filtration. Multiple process parameters such as pH, temperature, concentration and time are controlled in each step to produce conjugates with desired properties.

[0185] Polysaccharide size reduction and oxidation

[0186] The purified pneumococcal capsular Ps powder was dissolved in water and subjected to 0.45 micron filtration. The size of the dissolved polysaccharides was reduced by adding aceti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in whichcapsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.

Description

technical field [0001] The present invention provides purified capsular polysaccharides from S. pneumoniae serotype 24F, as well as polysaccharide-protein conjugates with polysaccharides from this serotype. Polysaccharide-protein conjugates from this serotype can be included in multivalent pneumococcal conjugate vaccines. Background technique [0002] Streptococcus pneumoniae is an encapsulated bacterium and is an important cause of severe disease worldwide. In 1997, the Centers for Disease Control and Prevention (CDC) estimated that there were 3,000 cases of pneumococcal meningitis, 50,000 cases of pneumococcal bacteremia, 7,000,000 cases of pneumococcal otitis media, and 500,000 cases of pneumococcal pneumonia in the United States each year. See Centers for Disease Control and Prevention, MMWR Morb Mortal Wkly Rep 1997, 46(RR-8): 1-13. In addition, complications of these diseases can be severe, with some studies reporting mortality rates as high as 8% for pneumococcal me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/35A61K31/715A61K39/085C12P19/04
CPCA61K47/6415A61K47/646C12P19/04A61K39/092A61K2039/55505A61K2039/6037A61K2039/70A61K47/02A61K47/183A61K47/26C08B37/006C08B37/0003
Inventor R·J·波拉姆博C·阿拜古纳瓦达纳L·K·穆塞M·J·科辛斯基Y·A·崔P·麦克休J·科涅特兹克
Owner MERCK SHARP & DOHME BV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com